{"id":60563,"date":"2024-10-15T12:05:29","date_gmt":"2024-10-15T12:05:29","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/10\/15\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/"},"modified":"2024-10-15T12:05:29","modified_gmt":"2024-10-15T12:05:29","slug":"fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/","title":{"rendered":"FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer\u2019s Studies, Paving the Way to NDAs"},"content":{"rendered":"<div>\n<p>MALVERN, Pa., Oct.  15, 2024  (GLOBE NEWSWIRE) &#8212; via IBN \u2013 Annovis Bio Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), announced today the successful outcome of the End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on October 10, 2024. During the meeting, the FDA granted clearance to proceed with pivotal Phase 3 studies, based on the Company&#8217;s Phase 2\/3 clinical data showing symptomatic improvement in early AD patients. Annovis and the FDA have now aligned on a development path for buntanetap towards the filing of New Drug Applications (NDAs), one for short-term and one for long-term efficacy.<\/p>\n<p>The Phase 3 program will investigate buntanetap in patients with early AD and will consist of two trials: a 6-month study aimed at confirming buntanetap\u2019s symptomatic effects and an 18-month study designed to demonstrate potential disease-modifying effects. While the Company plans to run both studies, the completion of a well-designed and well-executed 6-month trial may be sufficient to support an NDA filing, potentially within one year of the study\u2019s initiation.<\/p>\n<p>Additionally, the FDA raised no concerns about the Company\u2019s data on buntanetap\u2019s safety, including liver enzymes, drug interactions, dose selection, pharmacokinetics, and population pharmacokinetics and confirmed that development can proceed using the new crystal form of buntanetap.<\/p>\n<p>\u201cWe are now ready to move into the highly anticipated Phase 3 stage,\u201d said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio. \u201cOur priority is to bring the treatment to patients as early as possible, and we are committed to ensuring the next clinical trial is executed at the highest standards to attain an expedited NDA submission. Our team is already preparing for trial initiation early next year and will continue to keep you updated as we advance towards our goal.\u201d<\/p>\n<p><strong>About Annovis Bio, Inc.<\/strong><\/p>\n<p>Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company\u2019s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r0QCQl5IeOgjFhJxeTVNKt8rZTIhliy_6S83VDdc1h8htJZdQiSQ68n2tOr8S4BQbp6bnk7VZgi_b1E_qLARf9VebX-IuSF7a2iqUH28eKaOWCeMOMKtOVW4_dzKQEHPcuJFR9kMOelcktFKbFne-QvePP2quxSEPsgaEul_mEpAfPWlOtTyAILjR4WdqQ6b6-fJBkxr1bnKizs3aXUZSDprJ2AVen1WQU7h7D6brC3d4Av5ATkFCnltohq8Zq_SQqpA9SJ2wddRNJK3UTFscQ==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>www.annovisbio.com<\/u><\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=v0YkAyvFXlbYg814f2J7p8XebKX5BwaOvH_UNV4jOMaB8cvLadDZuZXNSohwEVXXIz9RP9azPiThVArgigAt0X30xybJAmQGwuiyaB_1HJgelt-bvQcMyq_b-1jUYHWA9nIjnwKAp6lg_GtcM6b6jLHvR-nsgndsqxBPehkE0KobVVWHvrQzHMI1InR8fef5dEu_ZbC4_osTDhXRi70vuRj01HWCaTGecLIIPLl_gE_sTRXFJrFyXFU7hOtd0AWQHbOzh5LUi42_bjcQuCmbsA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>LinkedIn<\/u><\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6BEmt-HMZ8TBRJ6E8eeJYLwZB-PaBibP8PgxllIaYnz_si8TzdMIcODlh6cpzcGMQUGwllKeJSh9DPLskxAJF6coRvfwoEtyUYMyEhouaU6nYk3_TnKtRThmrrbQByv_XT9dTOG3an1-x1K80xqU3UF16yTw5sany_HNAB1-_No5eRDznvDdqcr171uwYNi6MJ44H6_9zV4pOQAJrIbzC5etUXqLOXzCojZPLV2_UMMnIyAvhVAV0eakWXvTUp2Y\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>YouTube<\/u><\/a>, and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0vHYBoICnboMK4goKTeyaZz0ANFxB9WpL8WSYx7q5ms79V5xtPGSmqO4l5dJjHY9aclP-dLl4fKiafuvsLrqqLlMtxC6J0fXRc88VvBtdH29TnoGAjxV666qnD-Lu1-_h8eS7LABDKqFtjgZtmpZr-QOU-hHo__A3rbP4evcX5RhRhrpC7hhb4pREO2y35qcMO8FoKAqkmXTb2RDXO8m5w==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>X<\/u><\/a>.<\/p>\n<p><strong>Investor Alerts<\/strong><\/p>\n<p>Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HI0oHGsVH4n-Xxj2QsiXaVyZLt9Cyf4jaenQcxCDAuMnDt62xNTwddRIh-3Ua23VKs0fUbtXwd5BCA1_YwA7_cBSQwvvhFWiyoyekMcCPIHe__kzZuEaS3QAh5PKwiBDmwqDjVqWFNjBTt8J8R1qbTL0sYU3pLEtwJ3_MqBBjOscqpwT7K-2GI1vDhz0l37sSDtkh_hEJxVq4Zx7JW4JUMj3FI641QfUc2Phsq5Wzv5boq4pF2ekPuTmYx35VE9uXuSm-xzxdP2eQbpt5FANgf2QaJ4Jg0Uird3RJ0toMfiotAVJ093ge-gGa-t5HaYZYFt99BW7elSe2A261jmz2TFcTDyePLyiSXl0qeZfn-8=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>https:\/\/www.annovisbio.com\/email-alerts<\/u><\/a>. Additionally, we invite you to explore our updated\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zmhjlc3dL2fhqbn0efOiGZxJv0PyaZk8r0XIaVFlklerLJP9a66UkbZ8Cd-ybZKIUJru-Yn9rPV571iaRwaPy4MlXWmi5AsqvlRCPxxrWdwvZWzo7Alrr_dh_QvW2IXlMgDVcqfKeLNlyuXWZrcRU0EteRONQUgntN36cc7HA652GCzbf-ROxvaiCepeScilw6-vSKB9B7dY2UVHj08mXtlvr3bMC8DD8KxNn5bm87W0JfVQnIYq4wv9mW5-zszG-aGzzmcndaoTZeEf9xW53Hufv9gCXRbdKK-d_bBMS6E=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>investor website<\/u><\/a>, which provides comprehensive access to company news, financial reports, and other key information.<\/p>\n<p><strong>Forward-Looking Statements<\/strong><\/p>\n<p>This press release contains &#8220;forward-looking&#8221; statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company&#8217;s plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company&#8217;s clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company&#8217;s periodic filings with the SEC, including those listed in the &#8220;Risk Factors&#8221; section of the Company&#8217;s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.<\/p>\n<p><strong>Contact Information:<\/strong><br \/> Annovis Bio Inc.<br \/> 101 Lindenwood Drive<br \/> Suite 225<br \/> Malvern, PA 19355<br \/> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r0QCQl5IeOgjFhJxeTVNKiaptIfHzaCTieD9xxX1OXE9DMoYdLpydoKFXE8bSG8J0tuyQ8V0HMvdK0kAxa6JGmdkjwhJ2yLtTmSRoUcbfeuLOpddTi7aupciBfA1xJLmWlKC9J5cf54glAimJD5xeFnQjZPnKqs8A4DCLESoYmyhx-gO0A4BlfrojKfqkS3zBKQhMKHkY2V9Ep5kxy9mZv7jxOeS13hCDtI91v8ersxU5GAOu8h-98TLYM83jUsq7psBeub37rc8fKj2-NGbLg==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>www.annovisbio.com<\/u><\/a><\/p>\n<p><strong>Investor Contact:<\/strong><br \/> Scott McGowan<br \/> InvestorBrandNetwork (IBN)<br \/> Phone: 310.299.1717<br \/> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r0QCQl5IeOgjFhJxeTVNKkICYSa6SHZeLP0noSrSPcxWjpgXQWeeqXfRYkRyFhf0tDxUrWfQSG7CQiz5_L6ewtnIjnt46sPBQD_s3q0xLXKNftJbW55_p5OVFmNVmIYvBTW11hHQ5SRpHq2dEqDRDolSpXVXsR5J9UzA-fUbO8-ftvMD2GjaOWkhnEZJL_6OdpuZDFsI0IE-Rb_fmL9KGmtmjyqPllGY4Yxou9u302rtvtZM7C2pVGRA-3jYEVH-1S7SLXTzH67vvlNCh4VpdJSa4HPyzb8jj7MHuCUqnRWsjZITgRRhmU4swMmcNYHP13zmyjiymFdJLvdDwil2LrXpTS5y1XU_zszHTB2YqKA=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>www.annovisbio.com\/investors-relations<\/u><\/a><br \/> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rpvKvRFpIrhW9IBV1JVfqhhnVhhE0m8G_khokybKyhLjaGGo-nJyhuFfukv_heNOADRh_zxUx1SWaQgm4TSApPC9rdn52yeqThUbNFqJUYM=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>IR@annovisbio.com<\/u><\/a> <\/p>\n<p><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OTgzZGJkNmMtYjgyMC00M2YxLTkyMTUtNzZlY2RhYmRmY2U4LTUwMDA3ODQ2NQ==\/tiny\/Annovis-Bio-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) &#8212; via IBN \u2013 Annovis Bio Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), announced today the successful outcome of the End-of-Phase 2 meeting with the U.S. Food [&#8230;]\n","protected":false},"author":1,"featured_media":60564,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-60563","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer\u2019s Studies, Paving the Way to NDAs - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer\u2019s Studies, Paving the Way to NDAs\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) &#8212; via IBN \u2013 Annovis Bio Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a late-stage clin\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-15T12:05:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/10\/Annovis-Bio-Inc-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer\u2019s Studies, Paving the Way to NDAs\",\"datePublished\":\"2024-10-15T12:05:29+00:00\",\"dateModified\":\"2024-10-15T12:05:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/\"},\"wordCount\":666,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/\",\"name\":\"FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer\u2019s Studies, Paving the Way to NDAs - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-10-15T12:05:29+00:00\",\"dateModified\":\"2024-10-15T12:05:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer\u2019s Studies, Paving the Way to NDAs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer\u2019s Studies, Paving the Way to NDAs - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/","og_locale":"en_US","og_type":"article","og_title":"FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer\u2019s Studies, Paving the Way to NDAs","og_description":"MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) &#8212; via IBN \u2013 Annovis Bio Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a late-stage clin","og_url":"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-10-15T12:05:29+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/10\/Annovis-Bio-Inc-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer\u2019s Studies, Paving the Way to NDAs","datePublished":"2024-10-15T12:05:29+00:00","dateModified":"2024-10-15T12:05:29+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/"},"wordCount":666,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/","url":"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/","name":"FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer\u2019s Studies, Paving the Way to NDAs - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-10-15T12:05:29+00:00","dateModified":"2024-10-15T12:05:29+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer\u2019s Studies, Paving the Way to NDAs"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/60563","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=60563"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/60563\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/60564"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=60563"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=60563"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=60563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}